Xbrane Biopharma AB (publ) has carried out a primary issuance of shares of approximately SEK 380 million at a subscription price of SEK 135 per share. The subscription price was determined through an accelerated book-building procedure. A number of Swedish and international institutional investors, including Lancelot Asset Management, Serendipity Group, Swedbank Robur Fonder and TIN Fonder, have subscribed for shares in the transaction.

Xbrane Biopharma develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market.

Kempen & Co and Pareto Securities acted as Joint Global Coordinators and Joint Bookrunners. Handelsbanken Capital Markets acted as Co-Manager. Baker McKenzie Advokatbyrå acted as legal advisor to Xbrane Biopharma with an international capital markets team consisting of Joakim Falkner, Johanna Flink and Carl Isaksson in Stockholm as well as Adam Farlow and Charles Farnsworth in London.
Explore Our Newsroom